Validation of the Korean Migraine-Specific Quality of Life Questionnaire Version 2.1 in Episodic and Chronic Migraine

Aims: To evaluate the validity of the Korean Migraine-Specific Quality of Life Questionnaire version 2.1 (K-MSQ v 2.1) in patients with episodic migraine (EM) or chronic migraine (CM). Methods: Subjects were recruited from a headache clinic and completed several self-report instruments, including the K-MSQ v 2.1, the Migraine Disability Assessment Scale (MIDAS), the Headache Impact Test-6 (HIT-6), the Migraine-Specific Quality of Life (MSQoL), the Patient Health Questionnaire-9 (PHQ-9), and the Generalized Anxiety Disorder-7 (GAD-7). Some of the subjects were assessed 4 weeks later and underwent the K-MSQ v 2.1 to examine test-retest reproducibility. Internal consistency and test-retest reproducibility were assessed to determine reliability. Construct validity was also assessed. Internal consistency (Cronbach's α) and test-retest reproducibility (intraclass correlation coefficients) were assessed to determine reliability. Pearson correlations were used to determine the validity. Results: For the 180 eligible patients, the value of Cronbach’s α for the three dimensions of the K-MSQ v. 2.1 (Role Function-Restrictive, Role Function-Preventive, and Emotional Function) were 0.954, 0.909, and 0.898, respectively, indicating excellent internal consistency. The intraclass correlation coefficients between baseline and the 4-week retest showed reliable reproducibility. The scores of the three dimensions for the K-MSQ v. 2.1 were well correlated with scores for the MIDAS, the HIT-6, the MSQoL, the PHQ-9, and the GAD-7. Internal consistency and construct validity showed similar tendencies in patients with EM and those with CM. Conclusion: The K-MSQ v 2.1 is a reliable and valid screening tool for evaluating QoL in patients with EM and CM.

chronic migraine; migraine; MSQ; quality of life; validation

1. Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and burden of migraine in the United States: Data from the American Migraine Study II. Headache 2001;41: 646–657.

2. Global Burden of Disease Study 2013 Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: A systematic analysis for the Global Burden of Disease Study 2013. Lancet 2015;386:743–800.

3. Hamelsky SW, Lipton RB, Stewart WF. An assessment of the burden of migraine using the willingness to pay model. Cephalalgia 2005;25:87–100.

4. Katsarava Z, Buse DC, Manack AN, Lipton RB. Defining the differences between episodic migraine and chronic migraine. Curr Pain Headache Rep 2012;16:86–92.

5. Sanders C, Egger M, Donovan J, Tallon D, Frankel S. Reporting on quality of life in randomised controlled trials: Bibliographic study. BMJ 1998;317:1191–1194.

6. Calvert MJ, Freemantle N. Use of health-related quality of life in prescribing research. Part 1: Why evaluate health-related quality of life? J Clin Pharm Ther 2003;28:513–521.

7. Dahlöf CG, Dimenäs E. Migraine patients experience poorer subjective well-being/quality of life even between attacks. Cephalalgia 1995;15:31–36.

8. Stuginski-Barbosa J, Dach F, Bigal M, Speciali JG. Chronic pain and depression in the quality of life of women with migraine—A controlled study. Headache 2012;52:400–408.

9. Holroyd KA. Assessment and psychological management of recurrent headache disorders. J Consult Clin Psychol 2002; 70:656–677.

10. Fitzpatrick R, Davey C, Buxton MJ, Jones DR. Evaluating patient-based outcome measures for use in clinical trials. Health Technol Assess 1998;2:i–iv, 1–74.

11. Silberstein S, Tfelt-Hansen P, Dodick DW, et al. Guidelines for controlled trials of prophylactic treatment of chronic migraine in adults. Cephalalgia 2008;28:484–495.

12. Jhingran P, Osterhaus JT, Miller DW, Lee JT, Kirchdoerfer L. Development and validation of the migraine-specific quality of life questionnaire. Headache 1998;38:295–302.

13. Pathak D, Martin B, Kwong J, Batenhorst A. Evaluation of the Migraine-Specific Quality of Life Questionnaire (MSQ Version 2.0) using confirmatory factor analysis. Qual Life Res 1998;7:647.

14. Martin BC, Pathak DS, Sharfman MI, et al. Validity and reliability of the Migraine-Specific Quality of Life Questionnaire (MSQ Version 2.1). Headache 2000;40:204–215.

15. Bagley CL, Rendas-Baum R, Maglinte GA, et al. Validating migraine-specific quality of life questionnaire v2.1 in episodic and chronic migraine. Headache 2012;52:409–421.

16. Rendas-Baum R, Bloudek LM, Maglinte GA, Varon SF. The psychometric properties of the Migraine-Specific Quality of Life Questionnaire version 2.1 (MSQ) in chronic migraine patients. Qual Life Res 2013;22:1123–1133.

17. Cole JC, Lin P, Rupnow MF. Validation of the Migraine-Specific Quality of Life Questionnaire version 2.1 (MSQ v. 2.1) for patients undergoing prophylactic migraine treatment. Qual Life Res 2007;16:1231–1237.

18. Raggi A, Giovannetti AM, Schiavolin S, et al. Validating the Migraine-Specific Quality of Life Questionnaire v2.1 (MSQ) in Italian inpatients with chronic migraine with a history of medication overuse. Qual Life Res 2014;23:1273–1277.

19. Mula M, Viana M, Jauch R, et al. Health-related quality of life measures and psychiatric comorbidity in patients with migraine. Eur J Neurol 2009;16:1017–1021.

20. Dodick DW, Freitag F, Banks J, et al. Topiramate versus amitriptyline in migraine prevention: A 26-week, multicenter, randomized, double-blind, double-dummy, parallel-group noninferiority trial in adult migraineurs. Clin Ther 2009;31:542–559.

21. Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia 2013;33:629–808.

22. Lee HS, Chung CS, Song HJ, Park HS. The reliability and validity of the MIDAS (Migraine Disability Assessment) Questionnaire for Korean migraine sufferers. J Korean Neurol Assoc 2000;18:287–291.

23. Chu MK, Im HJ, Ju YS, et al. Validity and reliability assessment of Korean Headache Impact Test-6 (HIT-6). J Korean Neurol Assoc 2009;27:1–6.

24. Moon HS, Chung CS, Lee HS, Park HS, Kim SW, Woo HW. The reliability and validity of the Migraine-Specific Quality of Life Questionnaire for Korean migraine suffers. J Korean Neurol Assoc 2003;21:146–155.

25. Seo JG, Park SP. Validation of the Patient Health Questionnaire-9 (PHQ-9) and PHQ-2 in patients with migraine. J Headache Pain 2015;16:65.

26. Seo JG, Park SP. Validation of the Generalized Anxiety Disorder-7 (GAD-7) and GAD-2 in patients with migraine. J Headache Pain 2015;16:97.

27. Kosinski M, Bayliss MS, Bjorner JB, et al. A six-item short-form survey for measuring headache impact: The HIT-6. Qual Life Res 2003;12:963–974.

28. Bayliss M, Batenhorst A. The HIT-6™: A User’s Guide. Lincoln, RI: Quality Metric Inc, 2002.

29. Wagner TH, Patrick DL, Galer BS, Berzon RA. A new instrument to assess the long-term quality of life effects from migraine: Development and psychometric testing of the MSQOL. Headache 1996;36:484–492.

30. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: Validity of a brief depression severity measure. J Gen Intern Med 2001; 16:606–613.

31. Diagnostic and Statistical Manual of Mental Disorders, ed 3 [Revision]. New York: American Psychiatric Association, 1987.

32. Spitzer RL, Kroenke K, Williams JB, Löwe B. A brief measure for assessing generalized anxiety disorder: The GAD-7. Arch Intern Med 2006;166:1092–1097.

33. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977;33:159–174.

34. Zandifar A, Masjedi SS, Haghdoost F, et al. The psychometric properties of the Persian Migraine-Specific Quality of Life Questionnaire version 2.1 in episodic and chronic migraine. Sc ientificWorldJournal 2013;2013:950245.

35. Hartmaier SL, Santanello NC, Epstein RS, Silberstein SD. Development of a brief 24-hour migraine-specific quality of life questionnaire. Headache 1995;35:320–329.

36. Lantéri-Minet M, Radat F, Chautard MH, Lucas C. Anxiety and depression associated with migraine: Influence on migraine subjects’ disability and quality of life, and acute migraine management. Pain 2005;118:319–326.

37. Sareen J, Jacobi F, Cox BJ, Belik SL, Clara I, Stein MB. Disability and poor quality of life associated with comorbid anxiety disorders and physical conditions. Arch Intern Med 2006; 166:2109–2116.

38. Hung CI, Wang SJ, Yang CH, Liu CY. The impacts of migraine, anxiety disorders, and chronic depression on quality of life in psychiatric outpatients with major depressive disorder. J Psychosom Res 2008;65:135–142.

39. Kim SY, Park SP. The role of headache chronicity among predictors contributing to quality of life in patients with migraine: A hospital-based study. J Headache Pain 2014;15:68.